• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

GSK, Innoviva seek expanded label for triple inhaler

November 27, 2017 By Sarah Faulkner

GlaxoSmithKlineGlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) have submitted data from the landmark Impact trial to the FDA in the hopes of landing an expanded label for the Trelegy Ellipta triple inhaler.

The two companies are hoping that their therapy could be used to treat airflow obstruction and to reduce exacerbations in people with chronic obstructive pulmonary disease.

Trelegy Ellipta, which won FDA approval in September, is the first once-daily COPD therapy to combine three molecules in a single inhaler. GSK’s Ellipta dry powder inhaler delivers an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta2-adrenergic agonist. Right now, the product is approved for the long-term treatment of COPD in patients who are taking other medication but still need additional bronchodilation.

The Impact study found that the triple inhaler was better than dual combination therapies at lessening exacerbation rates and improving lung function, GSK reported.

“Data from GSK’s landmark Impact study provide important information on the efficacy and safety of these molecules combined in a single inhaler and the benefit they can bring to appropriate patients when delivered as a triple combination therapy,” GSK’s president of R&D, Patrick Vallance, said in prepared remarks. “We have moved swiftly to file these data with the FDA.”

“Trelegy Ellipta adds to the portfolio of Ellipta inhaled therapies, which has been developed because patients have different treatment needs,” Innoviva CEO Michael Aguiar added. “We believe the Impact data will provide clarity to physicians on how to treat patients based on their symptoms and risk profile and that Trelegy Ellipta will play an important role in treating patients who remain symptomatic and at risk of an exacerbation despite current therapy.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: GlaxoSmithKline plc, Innoviva

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS